BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens

Pathology International

Volumn 63, Issue 3, 2013, Pages 176-182

  Hosoda, Waki ^a   Sasaki, Eiichi ^a   Murakami, Yoshiko ^a   Yamao, Kenji ^b   Shimizu, Yasuhiro ^c   Yatabe, Yasushi ^a  

^a Departments of Thoracic Surgery Pathology and Molecular Diagnostics   (Japan)

^b Gastroenterology   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acinar cell carcinoma; BCL10; Differential diagnosis; Immunohistochemistry; Pancreatic cancer

Indexed keywords

GNAS PROTEIN; K RAS PROTEIN; PROTEIN; PROTEIN BCL 10; UNCLASSIFIED DRUG;

ACINAR CELL; ACINAR CELL CARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; CYSTADENOMA; CYTOLOGY; DIAGNOSTIC VALUE; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MUCINOUS CYSTIC NEOPLASM; NEUROENDOCRINE TUMOR; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; SOLID PSEUDOPAPILLARY TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; BIOPSY, FINE-NEEDLE; CARCINOMA, ACINAR CELL; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, PANCREATIC DUCTAL; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOSONOGRAPHY; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875679983     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12045     Document Type: Article

References (30)

1. Matsuno S, Egawa S, Fukuyama S etal. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004; 28: 219-230.
2. Klimstra DS, Hruban RH, Kloppel G etal. Acinar cell neoplasms of the pancreas. In: Bosman FT, Carnerio F, Hruban RH, Theise ND, eds. World Health Organization Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2010; 314-318.
3. Hoorens A, Lemoine NR, McLellan E etal. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol 1993; 143: 685-698.
4. Klimstra DS, Heffess CS, Oertel JE, Rosai J. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 1992; 16: 815-837.
5. La Rosa S, Adsay V, Albarello L etal. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: Insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol 2012; 36: 1782-1795.
6. Klimstra DS. Nonductal neoplasms of the pancreas. Mod Pathol 2007; 20 (Suppl 1): S94-112.
7. Pellegata NS, Sessa F, Renault B etal. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-1560.
8. Terhune PG, Heffess CS, Longnecker DS. Only wild-type c-Ki-ras codons 12, 13, and 61 in human pancreatic acinar cell carcinomas. Mol Carcinog 1994; 10: 110-114.
9. Moore PS, Orlandini S, Zamboni G etal. Pancreatic tumours: Molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001; 84: 253-262.
10. Willis TG, Jadayel DM, Du MQ etal. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96: 35-45.
11. Zhang Q, Siebert R, Yan M etal. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 1999; 22: 63-68.
12. Thome M, Weil R. Post-translational modifications regulate distinct functions of CARMA1 and BCL10. Trends Immunol 2007; 28: 281-288.
13. Takahashi H, Hosokawa Y, Suzuki R, Morishima Y, Nakamura S, Seto M. Infrequent BCL10 mutations in B-cell non-Hodgkin's lymphomas. Jpn J Cancer Res 1999; 90: 1316-1320.
14. Du MQ, Peng H, Liu H etal. BCL10 gene mutation in lymphoma. Blood 2000; 95: 3885-3890.
15. Morin RD, Mendez-Lago M, Mungall AJ etal. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
16. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
17. Chang HH, Kuo MY, Cheng SJ, Chiang CP. Expression of BCL10 is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. Oral Oncol 2009; 45: 589-593.
18. Kuo SH, Chou CH, Cheng AL, Wang CW, Chen YH, Chen RJ. Expression of BCL10 in cervical cancer has a role in the regulation of cell growth through the activation of NF-kappaB-dependent cyclin D1 signaling. Gynecol Oncol 2012; 126: 245-251.
19. La Rosa S, Franzi F, Marchet S etal. The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch 2009; 454: 133-142.
20. Yamao K, Sawaki A, Mizuno N, Shimizu Y, Yatabe Y, Koshikawa T. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB): Past, present, and future. J Gastroenterol 2005; 40: 1013-1023.
21. Hosoda W, Takagi T, Mizuno N etal. Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration. Pathol Int 2010; 60: 358-364.
22. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006; 8: 335-341.
23. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-1249.
24. Kitago M, Ueda M, Aiura K etal. Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int J Cancer 2004; 110: 177-182.
25. Schonleben F, Qiu W, Bruckman KC etal. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett 2007; 249: 242-248.
26. Wu J, Matthaei H, Maitra A etal. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011; 3: 92ra66.
27. Furukawa T, Kuboki Y, Tanji E etal. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011; 1: 161.
28. Rooman I, Real FX. Pancreatic ductal adenocarcinoma and acinar cells: A matter of differentiation and development? Gut 2012; 61: 449-458.
29. Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol 2010; 34: 510-518.
30. Moar-Antelo AR, Perez-Sayans M, Suarez-Penaranda JM etal. BCL10 expression is unrelated to clinico-pathological parameters or prognoses for oral squamous cell carcinomas. Biotech Histochem 2012; 87: 423-427.